Keywords
Last Name
Institution

GUILLERMINA LOZANO

TitleProfessor
InstitutionMD Anderson
DepartmentGenetics
Address6767 Bertner St
Houston TX 77030-2603
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, Karpiuk O, Kassem M, Zhang Y, Lozano G, Johnsen SA, Moll UM, Zhang X, Dobbelstein M. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Mol Cell. 2016 Jan 7; 61(1):68-83. PMID: 26748827.
      View in: PubMed
    2. Mitani Y, Liu B, Rao PH, Borra VJ, Zafereo M, Weber RS, Kies M, Lozano G, Futreal PA, Caulin C, El-Naggar AK. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clin Cancer Res. 2016 Feb 1; 22(3):725-33. PMID: 26631609; PMCID: PMC4807116 [Available on 02/01/17].
    3. Kim MP, Zhang Y, Lozano G. Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer. Front Oncol. 2015; 5:249. PMID: 26618142.
      View in: PubMed
    4. Tashakori M, Zhang Y, Xiong S, You MJ, Lozano G. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Mol Cancer Res. 2016 Jan; 14(1):56-65. PMID: 26527653.
      View in: PubMed
    5. Goh AM, Xue Y, Leushacke M, Li L, Wong JS, Chiam PC, Rahmat SA, Mann MB, Mann KM, Barker N, Lozano G, Terzian T, Lane DP. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget. 2015 Jul 20; 6(20):17968-80. PMID: 26255629.
      View in: PubMed
    6. Riley MF, You MJ, Multani AS, Lozano G. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene. 2016 Jan 21; 35(3):358-65. PMID: 25915849.
      View in: PubMed
    7. Jiang S, Minter LC, Stratton SA, Yang P, Abbas HA, Akdemir ZC, Pant V, Post S, Gagea M, Lee RG, Lozano G, Barton MC. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol. 2015 Feb; 62(2):371-9. PMID: 25281858.
      View in: PubMed
    8. Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev. 2014 Aug 15; 28(16):1739-51. PMID: 25128494.
      View in: PubMed
    9. Quintás-Cardama A, Post SM, Solis LM, Xiong S, Yang P, Chen N, Wistuba II, Killary AM, Lozano G. Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer. J Pathol. 2014 Sep; 234(1):108-19. PMID: 24890125.
      View in: PubMed
    10. Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, Rotter V, Liu B, El-Naggar AK, Donehower LA, Martinez LA, Lozano G. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A. 2014 Jul 29; 111(30):11145-50. PMID: 25024203; PMCID: PMC4121829.
    11. Zhang Y, Xiong S, Li Q, Hu S, Tashakori M, Van Pelt C, You MJ, Pageon L, Lozano G. Tissue-specific and age-dependent effects of global Mdm2 loss. J Pathol. 2014 Aug; 233(4):380-91. PMID: 24789767.
      View in: PubMed
    12. Zou Q, Jin J, Hu H, Li HS, Romano S, Xiao Y, Nakaya M, Zhou X, Cheng X, Yang P, Lozano G, Zhu C, Watowich SS, Ullrich SE, Sun SC. USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nat Immunol. 2014 Jun; 15(6):562-70. PMID: 24777531; PMCID: PMC4032322.
    13. Pant V, Lozano G. Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity. Oncotarget. 2014 Mar 15; 5(5):1149-56. PMID: 24658419.
      View in: PubMed
    14. Ma J, Xiong M, You M, Lozano G, Amos CI. Genome-wide association tests of inversions with application to psoriasis. Hum Genet. 2014 Aug; 133(8):967-74. PMID: 24623382; PMCID: PMC4281304.
    15. Eischen CM, Lozano G. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat. 2014 Jun; 35(6):728-37. PMID: 24488925.
      View in: PubMed
    16. Li Q, Zhang Y, El-Naggar AK, Xiong S, Yang P, Jackson JG, Chau G, Lozano G. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. Mol Cancer Res. 2014 Jun; 12(6):901-11. PMID: 24598047.
      View in: PubMed
    17. Tordella L, Koch S, Salter V, Pagotto A, Doondeea JB, Feller SM, Ratnayaka I, Zhong S, Goldin RD, Lozano G, McKeon FD, Tavassoli M, Fritzsche F, Huber GF, Rössle M, Moch H, Lu X. ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Proc Natl Acad Sci U S A. 2013 Oct 29; 110(44):17969-74. PMID: 24127607.
      View in: PubMed
    18. Pant V, Xiong S, Jackson JG, Post SM, Abbas HA, Quintás-Cardama A, Hamir AN, Lozano G. The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity. Genes Dev. 2013 Sep 1; 27(17):1857-67. PMID: 23973961; PMCID: PMC3778240.
    19. Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS, Abruzzo LV, Rashid A, Rodriguez J, Lozano G, Cao Y, Lokken E, Chen J, Frazier ML, Sahin AA, Wistuba II, Sen S, Lott ST, Killary AM. DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-?-driven epithelial-mesenchymal transition. Cancer Discov. 2013 Oct; 3(10):1172-89. PMID: 23838884; PMCID: PMC4107927.
    20. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Rozenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG, Oren M. Mutant p53 prolongs NF-?B activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013 May 13; 23(5):634-46. PMID: 23680148.
      View in: PubMed
    21. Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, Pandolfi PP, Castillo-Martin M, Bonal DM, Cordon-Cardo C, Lozano G, Haupt Y. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle. 2013 Jun 1; 12(11):1722-31. PMID: 23656786; PMCID: PMC3713131.
    22. Chen YC, Chan JY, Chiu YL, Liu ST, Lozano G, Wang SL, Ho CL, Huang SM. Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis. Cell Death Differ. 2013 May; 20(5):732-43. PMID: 23370271.
      View in: PubMed
    23. Jackson JG, Lozano G. The mutant p53 mouse as a pre-clinical model. Oncogene. 2013 Sep 12; 32(37):4325-30. PMID: 23318424.
      View in: PubMed
    24. Li Q, Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res. 2013 Jan 1; 19(1):34-41. PMID: 23262034; PMCID: PMC3537867.
    25. Pant V, Quintás-Cardama A, Lozano G. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood. 2012 Dec 20; 120(26):5118-27. PMID: 23018641; PMCID: PMC3537308.
    26. Flores ER, Lozano G. The p53 family grows old. Genes Dev. 2012 Sep 15; 26(18):1997-2000. PMID: 22987633; PMCID: PMC3444725.
    27. Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS. AACR Cancer Progress Report 2012. Clin Cancer Res. 2012 Nov 1; 18(21 Suppl):S1-100. PMID: 22977188.
      View in: PubMed
    28. Jackson JG, Lozano G. Che-ating death: CHE1/AATF protects from p53-mediated apoptosis. EMBO J. 2012 Oct 17; 31(20):3951-3. PMID: 22960635; PMCID: PMC3474930.
    29. Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell. 2012 Jun 12; 21(6):793-806. PMID: 22698404; PMCID: PMC3376352.
    30. Hallenborg P, Feddersen S, Francoz S, Murano I, Sundekilde U, Petersen RK, Akimov V, Olson MV, Lozano G, Cinti S, Gjertsen BT, Madsen L, Marine JC, Blagoev B, Kristiansen K. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death Differ. 2012 Aug; 19(8):1381-9. PMID: 22388350; PMCID: PMC3392627.
    31. Riley MF, Lozano G. The Many Faces of MDM2 Binding Partners. Genes Cancer. 2012 Mar; 3(3-4):226-39. PMID: 23150756; PMCID: PMC3494375.
    32. Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K, Oren M. Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death Differ. 2012 Jan; 19(1):180-3. PMID: 22095277.
      View in: PubMed
    33. Lin S, Yu L, Yang J, Liu Z, Karia B, Bishop AJ, Jackson J, Lozano G, Copland JA, Mu X, Sun B, Sun LZ. Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-ß (TGF-ß). J Biol Chem. 2011 Dec 23; 286(51):44023-34. PMID: 22039050.
      View in: PubMed
    34. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T, Lozano G. Multiple stress signals activate mutant p53 in vivo. Cancer Res. 2011 Dec 1; 71(23):7168-75. PMID: 21983037; PMCID: PMC3320147.
    35. Abbas HA, Pant V, Lozano G. The ups and downs of p53 regulation in hematopoietic stem cells. Cell Cycle. 2011 Oct 1; 10(19):3257-62. PMID: 21957490.
      View in: PubMed
    36. McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, Krafcik F, Rodriguez-Galindo C, Wilson M, Xiong S, Lozano G, Sage J, Fu L, Louhibi L, Trimarchi J, Pani A, Smeyne R, Johnson D, Dyer MA. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell. 2011 Aug 16; 20(2):260-75. PMID: 21840489; PMCID: PMC3551581.
    37. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, Mano M, Rosato A, Crook T, Scanziani E, Means AR, Lozano G, Schneider C, Del Sal G. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011 Jul 12; 20(1):79-91. PMID: 21741598.
      View in: PubMed
    38. Pant V, Xiong S, Iwakuma T, Quintás-Cardama A, Lozano G. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A. 2011 Jul 19; 108(29):11995-2000. PMID: 21730132; PMCID: PMC3141986.
    39. Terzian T, Dumble M, Arbab F, Thaller C, Donehower LA, Lozano G, Justice MJ, Roop DR, Box NF. Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. J Pathol. 2011 Aug; 224(4):540-52. PMID: 21674502; PMCID: PMC3632393.
    40. Williams MD, Zhang L, Elliott DD, Perrier ND, Lozano G, Clayman GL, El-Naggar AK. Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. Hum Pathol. 2011 Sep; 42(9):1213-20. PMID: 21420716; PMCID: PMC3156288.
    41. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintás-Cardama A, Bankson JA, El-Naggar AK, Lozano G. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011 Mar; 121(3):893-904. PMID: 21285512.
      View in: PubMed
    42. Wu CC, Krahe R, Lozano G, Zhang B, Wilson CD, Jo EJ, Amos CI, Shete S, Strong LC. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Hum Genet. 2011 Jun; 129(6):663-73. PMID: 21305319; PMCID: PMC4194062.
    43. Zhao R, Yeung SC, Chen J, Iwakuma T, Su CH, Chen B, Qu C, Zhang F, Chen YT, Lin YL, Lee DF, Jin F, Zhu R, Shaikenov T, Sarbassov D, Sahin A, Wang H, Wang H, Lai CC, Tsai FJ, Lozano G, Lee MH. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest. 2011 Mar; 121(3):851-65. PMID: 21317535.
      View in: PubMed
    44. Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, Powell MB, Pollock PM, Lozano G, Robinson WA, Roop DR, Box NF. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res. 2010 Dec; 23(6):781-94. PMID: 20849464; PMCID: PMC3137930.
    45. Abbas HA, Maccio DR, Coskun S, Jackson JG, Hazen AL, Sills TM, You MJ, Hirschi KK, Lozano G. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell. 2010 Nov 5; 7(5):606-17. PMID: 21040902; PMCID: PMC3026610.
    46. Jackson JG, Post SM, Lozano G. Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. J Pathol. 2011 Jan; 223(2):127-36. PMID: 20957626.
      View in: PubMed
    47. Terzian T, Lozano G. Building p53. Genes Dev. 2010 Oct 15; 24(20):2229-32. PMID: 20952532.
      View in: PubMed
    48. Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, Apte RN, Neeman M, Oren M. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res. 2010 Dec 1; 70(23):9650-8. PMID: 20952507; PMCID: PMC2999653.
    49. Lin PP, Wang Y, Lozano G. Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. Sarcoma. 2011; 2011. PMID: 20953407.
      View in: PubMed
    50. Post SM, Lozano G. You can win by losing: p53 mutations in rhabdomyosarcomas. J Pathol. 2010 Oct; 222(2):124-8. PMID: 20821751.
      View in: PubMed
    51. Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, Maccio DR, Bond GL, Johnson DG, Levine AJ, Lozano G. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010 Sep 14; 18(3):220-30. PMID: 20832750; PMCID: PMC2944041.
    52. Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene. 2010 Nov 18; 29(46):6125-37. PMID: 20802511.
      View in: PubMed
    53. Xiong S, Pant V, Suh YA, Van Pelt CS, Wang Y, Valentin-Vega YA, Post SM, Lozano G. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res. 2010 Sep 15; 70(18):7148-54. PMID: 20736370; PMCID: PMC2940952.
    54. Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One. 2010; 5(5):e10813. PMID: 20520810; PMCID: PMC2877078.
    55. Nurieva RI, Zheng S, Jin W, Chung Y, Zhang Y, Martinez GJ, Reynolds JM, Wang SL, Lin X, Sun SC, Lozano G, Dong C. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity. 2010 May 28; 32(5):670-80. PMID: 20493730; PMCID: PMC2915546.
    56. Odvody J, Vincent T, Arrate MP, Grieb B, Wang S, Garriga J, Lozano G, Iwakuma T, Haines DS, Eischen CM. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene. 2010 Jun 3; 29(22):3287-96. PMID: 20305689; PMCID: PMC2880662.
    57. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 2010 Jan; 17(1):93-102. PMID: 19498444.
      View in: PubMed
    58. Lozano G. Mouse models of p53 functions. Cold Spring Harb Perspect Biol. 2010 Apr; 2(4):a001115. PMID: 20452944; PMCID: PMC2845198.
    59. Post SM, Quintás-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene. 2010 Mar 4; 29(9):1260-9. PMID: 19935700.
      View in: PubMed
    60. Martinez LA, Goluszko E, Chen HZ, Leone G, Post S, Lozano G, Chen Z, Chauchereau A. E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol. 2010 Jan; 30(2):524-36. PMID: 19917728; PMCID: PMC2798461.
    61. Donehower LA, Lozano G. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer. 2009 Nov; 9(11):831-41. PMID: 19776746.
      View in: PubMed
    62. Lin PP, Pandey MK, Jin F, Raymond AK, Akiyama H, Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis. 2009 Oct; 30(10):1789-95. PMID: 19635748; PMCID: PMC4141195.
    63. Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One. 2009; 4(4):e5401. PMID: 19404390; PMCID: PMC2671160.
    64. Valentin-Vega YA, Box N, Terzian T, Lozano G. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation. 2009 Jun; 77(5):442-9. PMID: 19371999; PMCID: PMC4041067.
    65. Eischen CM, Lozano G. p53 and MDM2: antagonists or partners in crime? Cancer Cell. 2009 Mar 3; 15(3):161-2. PMID: 19249672.
      View in: PubMed
    66. Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, Tzahor E, Lozano G, Zipori D, Sarig R, Rotter V. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One. 2008; 3(11):e3707. PMID: 19002260.
      View in: PubMed
    67. Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM, Lozano G. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res. 2008 Nov 1; 68(21):8968-75. PMID: 18974141; PMCID: PMC4167779.
    68. Valentin-Vega YA, Okano H, Lozano G. The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ. 2008 Nov; 15(11):1772-81. PMID: 18636077; PMCID: PMC2742618.
    69. Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res. 2008 Jun; 6(6):947-54. PMID: 18567799.
      View in: PubMed
    70. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008 May 15; 22(10):1337-44. PMID: 18483220.
      View in: PubMed
    71. Atwal GS, Rabadán R, Lozano G, Strong LC, Ruijs MW, Schmidt MK, van't Veer LJ, Nevanlinna H, Tommiska J, Aittomäki K, Bougeard G, Frebourg T, Levine AJ, Bond GL. An information-theoretic analysis of genetics, gender and age in cancer patients. PLoS One. 2008; 3(4):e1951. PMID: 18398474; PMCID: PMC2276689.
    72. Liu G, Terzian T, Xiong S, Van Pelt CS, Audiffred A, Box NF, Lozano G. The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol. 2007 Dec; 213(4):360-8. PMID: 17893884.
      View in: PubMed
    73. Iwakuma T, Tochigi Y, Van Pelt CS, Caldwell LC, Terzian T, Parant JM, Chau GP, Koch JG, Eischen CM, Lozano G. Mtbp haploinsufficiency in mice increases tumor metastasis. Oncogene. 2008 Mar 20; 27(13):1813-20. PMID: 17906694.
      View in: PubMed
    74. Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol. 2007 Oct; 38(10):1553-62. PMID: 17651783; PMCID: PMC2699677.
    75. Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai WW, Lozano G, Roop DR. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest. 2007 Jul; 117(7):1893-901. PMID: 17607363; PMCID: PMC1904325.
    76. Koch JG, Gu X, Han Y, El-Naggar AK, Olson MV, Medina D, Jerry DJ, Blackburn AC, Peltz G, Amos CI, Lozano G. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome. 2007 May; 18(5):300-9. PMID: 17557176.
      View in: PubMed
    77. Xiong S, Van Pelt CS, Elizondo-Fraire AC, Fernandez-Garcia B, Lozano G. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation. 2007 Jun 12; 115(23):2925-30. PMID: 17533180.
      View in: PubMed
    78. Terzian T, Wang Y, Van Pelt CS, Box NF, Travis EL, Lozano G. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol. 2007 Aug; 27(15):5479-85. PMID: 17526734; PMCID: PMC1952101.
    79. Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene. 2007 Oct 18; 26(48):6896-904. PMID: 17486075.
      View in: PubMed
    80. Iwakuma T, Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene. 2007 Apr 2; 26(15):2177-84. PMID: 17401426.
      View in: PubMed
    81. Cosme-Blanco W, Shen MF, Lazar AJ, Pathak S, Lozano G, Multani AS, Chang S. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 2007 May; 8(5):497-503. PMID: 17396137; PMCID: PMC1866197.
    82. Lozano G, Behringer RR. New mouse models of cancer: single-cell knockouts. Proc Natl Acad Sci U S A. 2007 Mar 13; 104(11):4245-6. PMID: 17360508; PMCID: PMC1838586.
    83. Bu P, Evrard YA, Lozano G, Dent SY. Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Mol Cell Biol. 2007 May; 27(9):3405-16. PMID: 17325035; PMCID: PMC1899977.
    84. Lozano G. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev. 2007 Feb; 17(1):66-70. PMID: 17208429.
      View in: PubMed
    85. Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci U S A. 2006 Dec 26; 103(52):19842-7. PMID: 17170138; PMCID: PMC1702317.
    86. Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Medeiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, Barboza J, Jones DM, Rassidakis GZ, Kantarjian HM, Bueso-Ramos CE. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol. 2007 Jan; 20(1):54-62. PMID: 17143258.
      View in: PubMed
    87. Maetens M, Doumont G, Clercq SD, Francoz S, Froment P, Bellefroid E, Klingmuller U, Lozano G, Marine JC. Distinct roles of Mdm2 and Mdm4 in red cell production. Blood. 2007 Mar 15; 109(6):2630-3. PMID: 17105817.
      View in: PubMed
    88. Chandler DS, Singh RK, Caldwell LC, Bitler JL, Lozano G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res. 2006 Oct 1; 66(19):9502-8. PMID: 17018606.
      View in: PubMed
    89. Ayanga B, Price R, Gu X, Lozano G, Evans SC. Genetic mapping of a putative tumor suppressor locus that influences tumorigenesis and metastasis in mice. Genes Chromosomes Cancer. 2006 Jul; 45(7):668-75. PMID: 16586494.
      View in: PubMed
    90. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 2006 Jun; 13(6):927-34. PMID: 16543935.
      View in: PubMed
    91. Lee MH, Lozano G. Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol. 2006 Jun; 16(3):225-34. PMID: 16697215.
      View in: PubMed
    92. Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A. 2006 Feb 28; 103(9):3226-31. PMID: 16492743; PMCID: PMC1413885.
    93. Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol. 2006 Jan; 26(1):192-8. PMID: 16354690; PMCID: PMC1317622.
    94. Slack A, Lozano G, Shohet JM. MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett. 2005 Oct 18; 228(1-2):21-7. PMID: 15927364.
      View in: PubMed
    95. Iwakuma T, Lozano G, Flores ER. Li-Fraumeni syndrome: a p53 family affair. Cell Cycle. 2005 Jul; 4(7):865-7. PMID: 15917654.
      View in: PubMed
    96. Lozano G, Zambetti GP. Gankyrin: an intriguing name for a novel regulator of p53 and RB. Cancer Cell. 2005 Jul; 8(1):3-4. PMID: 16023592.
      View in: PubMed
    97. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005 Jun 10; 331(3):834-42. PMID: 15865939.
      View in: PubMed
    98. Huang W, Zhang J, Washington M, Liu J, Parant JM, Lozano G, Moore DD. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol. 2005 Jun; 19(6):1646-53. PMID: 15831521.
      View in: PubMed
    99. Liu G, Lozano G. p21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell. 2005 Feb; 7(2):113-4. PMID: 15710322.
      View in: PubMed
    100. Bachinski LL, Olufemi SE, Zhou X, Wu CC, Yip L, Shete S, Lozano G, Amos CI, Strong LC, Krahe R. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res. 2005 Jan 15; 65(2):427-31. PMID: 15695383.
      View in: PubMed
    101. Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? J Pathol. 2005 Jan; 205(2):206-20. PMID: 15643668.
      View in: PubMed
    102. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004 Dec 17; 119(6):861-72. PMID: 15607981.
      View in: PubMed
    103. Li Z, Day CP, Yang JY, Tsai WB, Lozano G, Shih HM, Hung MC. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res. 2004 Dec 15; 64(24):9080-5. PMID: 15604276.
      View in: PubMed
    104. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004 Nov 24; 119(5):591-602. PMID: 15550242.
      View in: PubMed
    105. Iwakuma T, Parant JM, Fasulo M, Zwart E, Jacks T, de Vries A, Lozano G. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene. 2004 Oct 7; 23(46):7644-50. PMID: 15361844.
      View in: PubMed
    106. Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, Miranda B, van Oostrom CT, van den Berg J, van den Aardweg GJ, Lozano G, van Steeg H, Jacks T, de Vries A. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol. 2004 Oct; 24(20):8884-94. PMID: 15456863.
      View in: PubMed
    107. Barlow JW, Mous M, Wiley JC, Varley JM, Lozano G, Strong LC, Malkin D. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. Cancer Epidemiol Biomarkers Prev. 2004 Aug; 13(8):1403-6. PMID: 15298965.
      View in: PubMed
    108. Evans SC, Liang M, Amos C, Gu X, Lozano G. A novel genetic modifier of p53, mop1, results in embryonic lethality. Mamm Genome. 2004 Jun; 15(6):415-23. PMID: 15181534.
      View in: PubMed
    109. Obeyesekere MN, Tecarro E, Lozano G. Model predictions of MDM2 mediated cell regulation. Cell Cycle. 2004 May; 3(5):655-61. PMID: 15107623.
      View in: PubMed
    110. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet. 2004 Jan; 36(1):63-8. PMID: 14702042.
      View in: PubMed
    111. Chavez-Reyes A, Parant JM, Amelse LL, de Oca Luna RM, Korsmeyer SJ, Lozano G. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res. 2003 Dec 15; 63(24):8664-9. PMID: 14695178.
      View in: PubMed
    112. Wong SS, Lozano G, Gaff CL, Gardner RJ, Strong LC, Aittomäki K, Lindeman GJ. Novel p53 germline mutation in a patient with Li-Fraumeni syndrome. Intern Med J. 2003 Dec; 33(12):621. PMID: 14656244.
      View in: PubMed
    113. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res. 2003 Dec; 1(14):993-1000. PMID: 14707282.
      View in: PubMed
    114. Horn EJ, Albor A, Liu Y, El-Hizawi S, Vanderbeek GE, Babcock M, Bowden GT, Hennings H, Lozano G, Weinberg WC, Kulesz-Martin M. RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis. 2004 Feb; 25(2):157-67. PMID: 14578165.
      View in: PubMed
    115. Yang HY, Wen YY, Chen CH, Lozano G, Lee MH. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol. 2003 Oct; 23(20):7096-107. PMID: 14517281.
      View in: PubMed
    116. Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet. 2003 Aug; 113(3):238-43. PMID: 12802680.
      View in: PubMed
    117. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003 Mar 21; 112(6):779-91. PMID: 12654245.
      View in: PubMed
    118. Parant JM, Lozano G. Disrupting TP53 in mouse models of human cancers. Hum Mutat. 2003 Mar; 21(3):321-6. PMID: 12619119.
      View in: PubMed
    119. Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003 Apr; 72(4):975-83. PMID: 12610779.
      View in: PubMed
    120. Lu X, Lozano G, Donehower LA. Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat Res. 2003 Jan 28; 522(1-2):69-83. PMID: 12517413.
      View in: PubMed
    121. Budhram-Mahadeo V, Morris P, Ndisang D, Irshad S, Lozano G, Pedley B, Latchman DS. The Brn-3a POU family transcription factor stimulates p53 gene expression in human and mouse tumour cells. Neurosci Lett. 2002 Dec 6; 334(1):1-4. PMID: 12431761.
      View in: PubMed
    122. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchénio T, Lozano G, Harel-Bellan A. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):14849-54. PMID: 12403821.
      View in: PubMed
    123. Jabbur JR, Tabor AD, Cheng X, Wang H, Uesugi M, Lozano G, Zhang W. Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21. Oncogene. 2002 Oct 10; 21(46):7100-13. PMID: 12370832.
      View in: PubMed
    124. Foster CJ, Lozano G. Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland. Oncogene. 2002 May 16; 21(22):3525-31. PMID: 12032854.
      View in: PubMed
    125. Santamaria AB, Davis DW, Nghiem DX, McConkey DJ, Ullrich SE, Kapoor M, Lozano G, Ananthaswamy HN. p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells. Cell Death Differ. 2002 May; 9(5):549-60. PMID: 11973613.
      View in: PubMed
    126. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem. 2002 May 31; 277(22):19251-4. PMID: 11953423.
      View in: PubMed
    127. Grier JD, Yan W, Lozano G. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis. 2002 Feb; 32(2):145-7. PMID: 11857803.
      View in: PubMed
    128. Schmidt M, Lu Y, Parant JM, Lozano G, Bacher G, Beckers T, Fan Z. Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies. Mol Pharmacol. 2001 Nov; 60(5):900-6. PMID: 11641417.
      View in: PubMed
    129. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet. 2001 Sep; 29(1):92-5. PMID: 11528400.
      View in: PubMed
    130. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene. 2001 Jul 5; 20(30):4041-9. PMID: 11494132.
      View in: PubMed
    131. Parant JM, Reinke V, Mims B, Lozano G. Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene. 2001 May 30; 270(1-2):277-83. PMID: 11404026.
      View in: PubMed
    132. El-Naggar AK, Lai S, Clayman GL, Mims B, Lippman SM, Coombes M, Luna MA, Lozano G. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis. 2001 May; 22(5):729-35. PMID: 11323391.
      View in: PubMed
    133. Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, Goodman R, Lozano G, Zhao Y, Lu H. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell. 2001 Feb; 7(2):283-92. PMID: 11239457.
      View in: PubMed
    134. Huang W, Wang SL, Lozano G, de Crombrugghe B. cDNA library screening using the SOS recruitment system. Biotechniques. 2001 Jan; 30(1):94-8, 100. PMID: 11196326.
      View in: PubMed
    135. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 2000 Sep 15; 14(18):2358-65. PMID: 10995391; PMCID: PMC316930.
    136. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4174-9. PMID: 10760284.
      View in: PubMed
    137. de Rozieres S, Maya R, Oren M, Lozano G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene. 2000 Mar 23; 19(13):1691-7. PMID: 10763826.
      View in: PubMed
    138. Lozano G, Elledge SJ. p53 sends nucleotides to repair DNA. Nature. 2000 Mar 2; 404(6773):24-5. PMID: 10716425.
      View in: PubMed
    139. Kapoor M, Hamm R, Yan W, Taya Y, Lozano G. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene. 2000 Jan 20; 19(3):358-64. PMID: 10656682.
      View in: PubMed
    140. Casau AE, Vaughan JE, Lozano G, Levine AJ. Germ cell expression of an isolated human endogenous retroviral long terminal repeat of the HERV-K/HTDV family in transgenic mice. J Virol. 1999 Dec; 73(12):9976-83. PMID: 10559311; PMCID: PMC113048.
    141. Keller D, Zeng X, Li X, Kapoor M, Iordanov MS, Taya Y, Lozano G, Magun B, Lu H. The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. Biochem Biophys Res Commun. 1999 Aug 2; 261(2):464-71. PMID: 10425208.
      View in: PubMed
    142. McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, Lozano G. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol. 1999 Jul; 188(3):322-8. PMID: 10419603.
      View in: PubMed
    143. Evans SC, Foster CJ, El-Naggar AK, Lozano G. Mapping and mutational analysis of the human TAF2G gene encoding a p53 cofactor. Genomics. 1999 Apr 1; 57(1):182-3. PMID: 10191103.
      View in: PubMed
    144. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M, Haupt Y. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 1999 Apr 1; 18(7):1805-14. PMID: 10202144; PMCID: PMC1171266.
    145. Reinke V, Bortner DM, Amelse LL, Lundgren K, Rosenberg MP, Finlay CA, Lozano G. Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ. 1999 Mar; 10(3):147-54. PMID: 10099828.
      View in: PubMed
    146. Hung J, Mims B, Lozano G, Strong L, Harvey C, Chen TT, Stastny V, Tomlinson G. TP53 mutation and haplotype analysis of two large African American families. Hum Mutat. 1999; 14(3):216-21. PMID: 10477429.
      View in: PubMed
    147. Kapoor M, Montes de Oca Luna R, Liu G, Lozano G, Cummings C, Mancini M, Ouspenski I, Brinkley BR, May GS. The cenpB gene is not essential in mice. Chromosoma. 1998 Dec; 107(8):570-6. PMID: 9933410.
      View in: PubMed
    148. Zou Y, Zong G, Ling YH, Hao MM, Lozano G, Hong WK, Perez-Soler R. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst. 1998 Aug 5; 90(15):1130-7. PMID: 9701362.
      View in: PubMed
    149. Evans SC, Mims B, McMasters KM, Foster CJ, deAndrade M, Amos CI, Strong LC, Lozano G. Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Hum Genet. 1998 Jun; 102(6):681-6. PMID: 9703430.
      View in: PubMed
    150. Anaya P, Evans SC, Dai C, Lozano G, May GS. Isolation of the Aspergillus nidulans sudD gene and its human homologue. Gene. 1998 May 12; 211(2):323-9. PMID: 9602165.
      View in: PubMed
    151. Lozano G, Montes de Oca Luna R. MDM2 function. Biochim Biophys Acta. 1998 Apr 17; 1377(2):M55-9. PMID: 9606977.
      View in: PubMed
    152. Kapoor M, Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2834-7. PMID: 9501176; PMCID: PMC19655.
    153. Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res. 1998 Feb 15; 58(4):698-703. PMID: 9485023.
      View in: PubMed
    154. Lozano G, Liu G. Mouse models dissect the role of p53 in cancer and development. Semin Cancer Biol. 1998; 8(5):337-44. PMID: 10101799.
      View in: PubMed
    155. Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M, McDonnell TJ. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene. 1997 Dec 4; 15(23):2767-72. PMID: 9419967.
      View in: PubMed
    156. Reinke V, Lozano G. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene. 1997 Sep 25; 15(13):1527-34. PMID: 9380404.
      View in: PubMed
    157. Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today. 1997 Sep; 3(9):390-5. PMID: 9302689.
      View in: PubMed
    158. Montes de Oca Luna R, Amelse LL, Chavez-Reyes A, Evans SC, Brugarolas J, Jacks T, Lozano G. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat Genet. 1997 Aug; 16(4):336-7. PMID: 9241268.
      View in: PubMed
    159. Reinke V, Lozano G. Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiat Res. 1997 Aug; 148(2):115-22. PMID: 9254729.
      View in: PubMed
    160. Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP, Finlay CA. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 1997 Mar 15; 11(6):714-25. PMID: 9087426.
      View in: PubMed
    161. Ruifrok AC, Mason KA, Lozano G, Thames HD. Spatial and temporal patterns of expression of epidermal growth factor, transforming growth factor alpha and transforming growth factor beta 1-3 and their receptors in mouse jejunum after radiation treatment. Radiat Res. 1997 Jan; 147(1):1-12. PMID: 8989363.
      View in: PubMed
    162. Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G. Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem. 1996 Nov 15; 271(46):29380-5. PMID: 8910602.
      View in: PubMed
    163. McMasters KM, Montes de Oca Luna R, Peña JR, Lozano G. mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene. 1996 Oct 17; 13(8):1731-6. PMID: 8895519.
      View in: PubMed
    164. Davis P, Bazar K, Huper G, Lozano G, Marks J, Iglehart JD. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene. 1996 Sep 19; 13(6):1315-22. PMID: 8808706.
      View in: PubMed
    165. de Oca Luna RM, Tabor AD, Eberspaecher H, Hulboy DL, Worth LL, Colman MS, Finlay CA, Lozano G. The organization and expression of the mdm2 gene. Genomics. 1996 May 1; 33(3):352-7. PMID: 8660994.
      View in: PubMed
    166. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 1995 Nov 9; 378(6553):203-6. PMID: 7477326.
      View in: PubMed
    167. de Vente JE, Kukoly CA, Bryant WO, Posekany KJ, Chen J, Fletcher DJ, Parker PJ, Pettit GJ, Lozano G, Cook PP, et al. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J Clin Invest. 1995 Oct; 96(4):1874-86. PMID: 7560079.
      View in: PubMed
    168. Ghebranious N, Knoll BJ, Yavorkovsky L, Ilic Z, Papaconstantinou J, Lozano G, Sell S. Developmental control of transcription of the CAT reporter gene by a truncated mouse alphafetoprotein gene regulatory region in transgenic mice. Mol Reprod Dev. 1995 Sep; 42(1):1-6. PMID: 8562043.
      View in: PubMed
    169. Deffie A, Hao M, Montes de Oca Luna R, Hulboy DL, Lozano G. Cyclin E restores p53 activity in contact-inhibited cells. Mol Cell Biol. 1995 Jul; 15(7):3926-33. PMID: 7791798.
      View in: PubMed
    170. Ghebranious N, Knoll BJ, Wu H, Lozano G, Sell S. Characterization of a murine p53ser246 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. Mol Carcinog. 1995 Jun; 13(2):104-11. PMID: 7605578.
      View in: PubMed
    171. Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol. 1994 Oct; 14(10):6858-67. PMID: 7935403; PMCID: PMC359216.
    172. Hulboy DL, Lozano G. Structural and functional analysis of p53: the acidic activation domain has transforming capability. Cell Growth Differ. 1994 Oct; 5(10):1023-31. PMID: 7848903.
      View in: PubMed
    173. Wu H, Lozano G. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem. 1994 Aug 5; 269(31):20067-74. PMID: 8051093.
      View in: PubMed
    174. Jiang D, Srinivasan A, Lozano G, Robbins PD. SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene. 1993 Oct; 8(10):2805-12. PMID: 8378089.
      View in: PubMed
    175. Deffie A, Wu H, Reinke V, Lozano G. The tumor suppressor p53 regulates its own transcription. Mol Cell Biol. 1993 Jun; 13(6):3415-23. PMID: 7684498; PMCID: PMC359810.
    176. Hao M, Finlay CA, Lozano G. A functionally inactive p53 Li-Fraumeni syndrome mutant. Oncogene. 1993 Feb; 8(2):299-306. PMID: 8426739.
      View in: PubMed
    177. Goldberg H, Helaakoski T, Garrett LA, Karsenty G, Pellegrino A, Lozano G, Maity S, de Crombrugghe B. Tissue-specific expression of the mouse alpha 2(I) collagen promoter. Studies in transgenic mice and in tissue culture cells. J Biol Chem. 1992 Sep 25; 267(27):19622-30. PMID: 1527081.
      View in: PubMed
    178. Raycroft L, Lozano G. A convenient cloning vector containing the GAL4 DNA-binding domain. Gene. 1992 Sep 1; 118(1):143-4. PMID: 1511878.
      View in: PubMed
    179. Beenken SW, Raycroft L, Lozano G. Inhibition of the mutant p53 gene in transformation assays. J Surg Res. 1992 Apr; 52(4):401-5. PMID: 1593878.
      View in: PubMed
    180. Raycroft L, Schmidt JR, Yoas K, Hao MM, Lozano G. Analysis of p53 mutants for transcriptional activity. Mol Cell Biol. 1991 Dec; 11(12):6067-74. PMID: 1944276.
      View in: PubMed
    181. Garofalo S, Vuorio E, Metsaranta M, Rosati R, Toman D, Vaughan J, Lozano G, Mayne R, Ellard J, Horton W, et al. Reduced amounts of cartilage collagen fibrils and growth plate anomalies in transgenic mice harboring a glycine-to-cysteine mutation in the mouse type II procollagen alpha 1-chain gene. Proc Natl Acad Sci U S A. 1991 Nov 1; 88(21):9648-52. PMID: 1946380.
      View in: PubMed
    182. Beenken SW, Karsenty G, Raycroft L, Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res. 1991 Sep 11; 19(17):4747-52. PMID: 1891364.
      View in: PubMed
    183. Lozano G, Levine AJ. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog. 1991; 4(1):3-9. PMID: 1848986.
      View in: PubMed
    184. Raycroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science. 1990 Aug 31; 249(4972):1049-51. PMID: 2144364; PMCID: PMC2935288.
    185. De Crombrugghe B, Karsenty G, Maity S, Vuorio T, Rossi P, Ruteshouser EC, McKinney SH, Lozano G. Transcriptional mechanisms controlling types I and III collagen genes. Ann N Y Acad Sci. 1990; 580:88-96. PMID: 2337308.
      View in: PubMed
    186. Marks J, Lin J, Miller D, Lozano G, Herbert J, Levine AJ. The expression of viral and cellular genes in papillomas of the choroid plexus induced in transgenic mice. Prog Clin Biol Res. 1988; 284:163-86. PMID: 2851142.
      View in: PubMed
    187. McCormick D, van der Rest M, Goodship J, Lozano G, Ninomiya Y, Olsen BR. Structure of the glycosaminoglycan domain in the type IX collagen-proteoglycan. Proc Natl Acad Sci U S A. 1987 Jun; 84(12):4044-8. PMID: 3473493; PMCID: PMC305018.
    188. Van Dyke TA, Finlay C, Miller D, Marks J, Lozano G, Levine AJ. Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. J Virol. 1987 Jun; 61(6):2029-32. PMID: 3033329.
      View in: PubMed
    189. Yagaloff KA, Lozano G, van Dyke T, Levine AJ, Hartig PR. Serotonin 5-HT1C receptors are expressed at high density on choroid plexus tumors from transgenic mice. Brain Res. 1986 Oct 22; 385(2):389-94. PMID: 3022874.
      View in: PubMed
    190. Lozano G, Ninomiya Y, Olsen BR. The structure of short-chain collagen genes. Prog Clin Biol Res. 1986; 217B:397-400. PMID: 3755828.
      View in: PubMed
    191. Ninomiya Y, van der Rest M, Mayne R, Lozano G, Olsen BR. Construction and characterization of cDNA encoding the alpha 2 chain of chicken type IX collagen. Biochemistry. 1985 Jul 16; 24(15):4223-9. PMID: 2996593.
      View in: PubMed
    192. Lozano G, Ninomiya Y, Thompson H, Olsen BR. A distinct class of vertebrate collagen genes encodes chicken type IX collagen polypeptides. Proc Natl Acad Sci U S A. 1985 Jun; 82(12):4050-4. PMID: 3858862; PMCID: PMC397932.
    193. Olsen BR, Ninomiya Y, Lozano G, Konomi H, Gordon M, Green G, Parsons J, Seyer J, Thompson H, Vasios G. Short-chain collagen genes and their expression in cartilage. Ann N Y Acad Sci. 1985; 460:141-53. PMID: 3868942.
      View in: PubMed
    194. Vogeli G, Avvedimento EV, Sullivan M, Maizel JV, Lozano G, Adams SL, Pastan I, de Crombrugghe B. Isolation and characterization of genomic DNA coding for alpha 2 type I collagen. Nucleic Acids Res. 1980 Apr 25; 8(8):1823-37. PMID: 7433131; PMCID: PMC324038.
    195. Lack of immunomodulatory interleukin-27 enhances oncogenic properties of mutant p53 in vivo. Clinical Cancer Research. 22:3876-3883.
    196. Signals regulating p53- and Rb-mediated negative cell growth. Cancer Bulletin. 47:158-162.
    197. Transcriptional Regulation by Tumor Suppressor Genes. Methods. 8:215-224.
    198. Mutant p53 Prolongs NF-kB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 24:272.
    199. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clinical Cancer Research. 22:725-733.
    200. Nuclear protein binds intron 4 of the p53 oncogene. Surgical Forum. 40:450-452.
    201. Attenuating the p53 pathway in human cancers. Cold Spring Harbor perspectives in medicine. 6.
    202. p53 activity dominates that of p73 upon Mdm4 loss in development and tumorigenesis. Molecular Cancer Research. 14:56-65.
    203. Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene.
    204. Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice. Oncotarget. 6:17968-17980.
    205. Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology.
    206. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Oncogene. 35:228-240.
    207. Mutant p53-driven tumorigenesis. 77-93.
    208. Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation. Cell Death and Differentiation. 23:509-520.
    209. The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. Journal of Pathology.
    210. Functional characterization of inherited p53 mutations. Cancer Bulletin. 46:247-253.
    211. Comparison of sample-labeling techniques in DNA microarray experiments. Analytica Chimica Acta. 506:117-125.
    212. Effects of MDM2, MDM4and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One. 5.
    213. Manipulating the p53 gene in the mouse. 183-207.
    214. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 523:352-356.
    215. Mutant p53. Frontiers in Oncology. 5.
    216. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma. Oncogene.
    217. Corrigendum. Nature. 527:398.
    218. Heterozygous p53V172F mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene.
    LOZANO's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description